Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
idecabtagene vicleucel · 1 trial · 1 indication
PFS as assessed by Independent Review Committee (IRC)
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| idecabtagene vicleucel | BIOLOGICAL | Specified dose on specified days |
| Lenalidomide | DRUG | Specified dose on specified days |
| Fludarabine | DRUG | Specified dose on specified days |
| Cyclophosphamide | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants aged ≥18 with Newly Diagnosed Multiple Myeloma (NDMM) who has received induction therapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), without subsequent consolidation or maintenance. EXCEPTION: Participant received ≤ 7 days of...
Top 20 of 25 competitors
Idecabtagene vicleucel is an investigational cell therapy being studied for the treatment of multiple myeloma. It is currently in Phase 3 clinical development for adult patients with newly diagnosed multiple myeloma who have a suboptimal response after autologous stem cell transplantation.
Idecabtagene vicleucel is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting a Phase 3 clinical trial to evaluate the therapy in patients with multiple myeloma.
Idecabtagene vicleucel is in Phase 3 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 3 trial is active but not recruiting participants.
Idecabtagene vicleucel is being studied in a Phase 3 clinical trial with the identifier NCT06045806. This randomized, active-controlled trial compares idecabtagene vicleucel plus lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adults with newly diagnosed multiple myeloma who have a suboptimal response after autologous stem cell transplantation.
Idecabtagene vicleucel is a cell therapy, classified as a -cel (cell therapy) modality. It is being investigated for its potential to treat multiple myeloma by targeting and eliminating cancer cells, though the specific molecular target is not disclosed in available information.